

Post-trans-arterial chemoembolization hepatic necrosis and biliary stenosis: Clinical characteristics and endoscopic approach

Silvia Cocca, Lorenzo Carloni, Margherita Marocchi, Giuseppe Grande, Marcello Bianchini, Antonio Colecchia, Rita Conigliaro, Helga Bertani

Specialty type: Gastroenterology and hepatology

Provenance and peer review:

Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Long X, China

Received: November 9, 2023

Peer-review started: November 9, 2023

First decision: November 22, 2023

Revised: December 1, 2023

Accepted: December 6, 2023

Article in press: December 6, 2023

Published online: December 26, 2023



Silvia Cocca, Margherita Marocchi, Giuseppe Grande, Rita Conigliaro, Helga Bertani, Gastroenterology and Endoscopy Unit, Azienda Ospedaliero Universitaria Policlinico di Modena, Modena 41121, Italy

Lorenzo Carloni, Department of Medical and Surgical Sciences, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna 00100, Italy

Marcello Bianchini, Antonio Colecchia, Department of Internal Medicine, Azienda Ospedaliero Universitaria Policlinico di Modena, Modena 41121, Italy

Corresponding author: Silvia Cocca, MD, PhD, Staff Physician, Gastroenterology and Endoscopy Unit, Azienda Ospedaliero Universitaria Policlinico di Modena, Via Pietro Giardini 1355, Modena 41121, Italy. silvia.cocca@gmail.com

Abstract

Liver cancer is the fifth most common tumor and the second highest death-related cancer in the world. Hepatocarcinoma (HCC) represents 90% of liver cancers. According to the Barcelona Clinic Liver Cancer group, different treatment options could be offered to patients in consideration of tumor burden, liver function, patient performance status and biochemical marker serum concentration such as alpha-fetoprotein. Trans-arterial chemoembolization (TACE) is the treatment of choice in patients with diagnosis of unresectable HCC not eligible for liver transplantation, and preserved arterial supply. TACE is known to be safe and its complications are generally mild such as post-TACE syndrome, a self-resolving adverse event that occurs in about 90% of patients after the procedure. However, albeit rarely, more severe adverse events such as biloma, sepsis, hepatic failure, chemoagents induced toxicities, and post-TACE liver necrosis can occur. A prompt diagnosis of these clinical conditions is fundamental to prevent further complications. As a result, biliary stenosis could be a rare post-TACE necrosis complication and can be difficult to manage. Complications from untreated biliary strictures include recurring infections, jaundice, chronic cholestasis, and secondary biliary cirrhosis.

Key Words: Hepatocarcinoma; Trans-arterial Chemoembolization; Biliary stenosis; Multistenting

Core Tip: Multifocal hepatocarcinoma (HCC) can benefit from local treatments with curative or down-staging purposes. Trans-arterial chemoembolization (TACE) is the treatment of choice in patients with a diagnosis of HCC not eligible for surgery (resection or liver transplantation) and ablation. TACE is known to be a safe procedure but can lead to both self-limiting mild adverse events and, albeit rarely, severe hepatic and biliary damage due to extensive hepatic ischemia.

Citation: Cocca S, Carloni L, Marocchi M, Grande G, Bianchini M, Colecchia A, Conigliaro R, Bertani H. Post-trans-arterial chemoembolization hepatic necrosis and biliary stenosis: Clinical characteristics and endoscopic approach. *World J Clin Cases* 2023; 11(36): 8434-8439

URL: <https://www.wjgnet.com/2307-8960/full/v11/i36/8434.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v11.i36.8434>

INTRODUCTION

Hepatocarcinoma (HCC) is the fifth most common and the second highest death-related cancer. It represents almost the totality of liver cancers and its incidence is increasing worldwide, mostly in Eastern countries and Africa[1]. Chronic liver disease, whatever the etiology, represents the major risk factor for HCC occurrence. Ultrasound (US), abdomen magnetic resonance imaging, and serum biochemical marker evaluation represent the validated diagnostic tools for early HCC detection in patients with advanced chronic liver disease[1]. According to tumor burden, liver function, and patient features (performance status, biomarker concentration, and prognostic score value such as Albumin-Bilirubin [ALBI]) Grade and Child-Pugh/MELD scores, several treatment options could be proposed to the patient[2]. Based to the latest Barcelona Clinic Liver Cancer update, liver transplantation (LT) is the treatment of choice when Milan Criteria are met or are achieved after disease down-staging[2,3]. In the case of focal HCC, surgery or local treatments [*i.e.* radiofrequency ablation, RFA, or microwave ablation (MWA)] could be proposed in consideration of patient surgical fitness. Whereas, in the case of multiple/diffuse HCC, local approaches [*i.e.* trans-arterial chemoembolization (TACE)] or immune/chemotherapy represent the best treatment options. Through the embolization of the feeding hepatic artery branches following the injection of multiple chemotherapy drugs, TACE robs tumors of their sustenance (*i.e.* ethiodized oil, gelatin powder, particles, and beads)[4]. The procedure is usually carried out through a right femoral approach: the catheter is advanced to the coeliac trifurcation where the common hepatic artery is catheterized and tumor arterial branches are reached up. Subsequently, chemo-agents are used to embolize neoplastic vasculature and lead to tumor necrosis. TACE is considered to be safe as well as effective for HCC, but nonvascular and vascular AE have been reported[1]. Among non-vascular complications, post-TACE syndrome presents in almost the totality of cases. Other nonvascular complications such as biloma, hepatic abscess, hepatic and renal failure, sepsis, pancreatitis, and toxicities induced by chemo-agents are possible [5,6]. Among the vascular AE, instead, post-TACE bile duct necrosis (BDN) and perforation have been reported[7].

CASE DESCRIPTION OF POST-TACE NECROSIS

We report a case of a 79-year-old woman with post-TACE hepatic hilar necrosis which resulted in serrated biliary stenosis. The patient was affected by hepatitis C virus related liver cirrhosis (Child-Pugh B7) complicated by hepatic encephalopathy, portal thrombosis, and multifocal HCC. Sustained virological response was achieved in 2016. In January 2023, for unresectable HCC recurrence in the caudate lobe, the patient underwent TACE. One month later, she was admitted to our hospital for persistent fever, abdominal pain, and jaundice. Abdominal imaging (US and CT) showed a cirrhotic liver with intrahepatic biliary dilation with solid tissue at the level of hilar bifurcation with substenosis. An endoscopic retrograde cholangiopancreatography (ERCP) and choledoscopy with Spyglass II was planned to study and characterize the biliary substenosis suitable for recurrence or necrosis and to treat the hilar stenosis. Biliary stenosis were seen during ERCP (Figure 1) and choledoscopy with Spyglass II revealed the presence of firm tissue strongly adherent to the biliary tree in the hepatic hilum (Figure 2). The histology report showed peri-bile duct tissue with necrotic changes, including coagulation necrosis and fibrinoid necrosis of the bile duct. After mechanical (Soehendra Biliary Dilation Catheter 4-6 Fr) and pneumatic dilatation (6 mm) of the intrahepatic ducts, two plastic stents (7 Fr × 15 cm) were placed in the left and right intrahepatic ducts to achieve proper biliary drainage. Moreover progressive pneumatic dilations (up to 8 mm) associated to multiple stenting replacement (up to 8.5 Fr × 12 cm) were subsequently performed to avoid jaundice recurrence and in the attempt to improve hilar stenosis. During follow-up the endoscopic treatment proved to be unsuccessful, given the persistence of biliary strictures together with the intrahepatic biliary dilation (Figure 3), suggesting permanent ischemic biliary damage. However, in light of the already compromised liver function and given the extent of the biliary damage, the patient was not eligible for other therapeutic options. The subsequent clinical, laboratory and radiological evaluations showed a stationary condition, and the patient showed no signs of obstructive jaundice at follow up.

Figure 1 Endoscopic retrograde cholangiopancreatography performed at admission to clarify the radiological findings showed a serrated biliary hilar stenosis (orange circle) and dilatation of intrahepatic bile ducts.





Figure 2 Choledoscopy with Spyglass II revealed the presence of fixed tissue in the hepatic hilum causing bile duct stenosis.

TACE is considered to be safe as well as effective for HCC, but, as already said, nonvascular and vascular AE have been reported[5]. Among the non-vascular complications, post-TACE syndrome presents in almost the totality of cases. It is characterized by fever, hypertransaminasemia, and right upper abdominal pain, but it is a clinical self-limiting condition lasting < 48 h. Beside post-TACE syndrome, other nonvascular complications such as biloma, hepatic and renal failure, sepsis, pancreatitis, and toxicities induced by chemo-agents can occur. Vascular AE include post-TACE hepatic necrosis and perforation. In particular, a rare occurrence of hepatic necrosis in a patient with a metastatic neuroendocrine tumor (NET) was reported by Micallef *et al*[4]. Kim *et al*[7] reported post-TACE duodenal perforation and esophageal ischemia in a man with unresectable HCC. Vascular thrombosis was detected on Doppler ultrasound and computed tomography scan (CT) in both reports, likely due to chemo-agents/arterial embolization induced ischemia, which probably plays a pivotal role in post-TACE necrosis and can lead to subsequent irreversible biliary stenosis.



DOI: 10.12998/wjcc.v11.i36.8434 Copyright ©The Author(s) 2023.

Figure 3 Magnetic resonance imaging cholangiopancreatography showing persistence of bile duct and intrahepatic biliary dilation after endoscopic treatment.

Hepatic arteries are the only blood vessels that supply the bile ducts. When the peribiliary vascular plexus or the tiny hepatic arteries are damaged, or when all arterial blood supplies are cut off, as in the case of a transplanted liver with hepatic artery thrombosis, an ischemic bile duct injury may result. Most causes of bile duct ischemia are iatrogenic: benign biliary stricture (BBS) represents the most frequently observed post-LT biliary complication[3]. However, liver necrosis and subsequent BS is a very rare complication after TACE, as the liver parenchyma receives a dual blood supply *via* the hepatic arteries and the hepatic portal veins[2]. It has only been reported in a few cases[8,9], therefore its incidence has not been clearly estimated. In the anecdotal cases found in the literature the most common outcome was death.

TACE should be suggested in patients with unresectable HCC[2] not eligible for LT and it is considered a safe procedure. However, in the described case, we have shown how TACE could be linked to severe vascular complications such as hepatic necrosis resulting in biliary tree stenosis. Although this AE is rare and unexpected, it may result in severe sequelae (*i.e.* jaundice, sepsis). That is why it should be considered if fever and abdominal pain are not self-limiting within 48 h and/or continue after analgesics administration[4,5]. Post-TACE biliary strictures can be diagnosed when signs and symptoms of biliary obstruction (abnormal liver function tests, jaundice, abdominal pain, and cholangitis) occur and in case of biliary dilatation on imaging. Localization and confirmation of the BS ultimately depends on cholangiography, either contrast-enhanced or magnetic resonance cholangiopancreatography (MRCP)[10].

ENDOSCOPIC TREATMENT OF BENIGN BILIARY STENOSIS

Endoscopy has become the preferred option for treating BBS, of which 85% are located in the common bile duct[11]. Unacceptably high adverse event rates and poor long-term results have led to the discontinuation of BBSs therapy with a single plastic stent or uncovered SEMS[11,12]. Therefore, the use of a single plastic stent as a first line of treatment should only be considered in very specific cases before engaging definite strategies.

Endoscopic treatment consists in multiple plastic stent (MPS) placement, balloon dilation, or a combination of these two techniques. The guidelines of the European Society of Gastrointestinal Endoscopy (ESGE) suggest inserting as many stents as feasible every 3 months for a total period of 12 months[11]. Plastic stents remain the gold standard for management of benign biliary strictures despite recent data demonstrating good and equal effectiveness of fully covered metal stents (FC-SEMS) in selected clinical scenarios[13,14]. With their larger diameters (10 mm *vs* 3.3 mm, respectively) and technical advantages—they are simpler to insert and take less time to place than MPS—they may be able to overcome some of the drawbacks of plastic stents[15]. However, using FC-SEMS presents a high risk of stent migration (around 9%), which varies significantly depending on the cause of the stenosis[14].

Technically speaking, hepatic and hilar strictures represent greater challenges for endoscopists. Percutaneous transhepatic cholangiography is one of the extra treatments that may be needed for the management of these strictures [10,11]. These kind of strictures are more common in individuals with primary sclerosing cholangitis (PSC). Short-term stents were not better than balloon dilatation in the first and only randomized trial of individuals with PSC with a prominent intrahepatic or hilar stricture, and they might even be harmful. Consequently, a very high rate of treatment-related adverse events, such as cholangitis, post-ERCP pancreatitis, and cholecystitis, necessitated the study's termination. Therefore, due to its ability to lower cholestasis, balloon dilatation ought to be the first treatment option for benign intrahepatic and hilar strictures[15,16].

CONCLUSION

For patients with intermediate-stage HCC with maintained liver function, TACE is currently the recommended type of treatment. It is a safe procedure that involves inserting synthetic materials and chemotherapy into a blood artery that feeds a tumor in order to interrupt its blood supply and trap the chemotherapy inside the tumor. However, TACE is associated with vascular and non-vascular adverse events. Non-vascular complications are biloma, hepatic and renal failure, sepsis, pancreatitis, and toxicities induced by chemo-agents; these adverse events are rare but extremely severe and can lead to patient death. The most common vascular AE is post-TACE syndrome which includes self-limiting fever, hypertransaminasemia, and right upper abdominal pain; post-TACE necrosis and perforation have been reported as well, and represent rare but severe vascular AE. We reported the first case of a severe biliary stricture induced by extensive post-TACE hepatic necrosis. Ischemic bile duct injury may occur when small hepatic arteries or the peribiliary vascular plexus are injured, or when all arterial blood supplies are interrupted, for example in transplanted liver with hepatic artery thrombosis. The clinical and biochemical examination (abnormal liver function tests, jaundice, abdominal discomfort, and cholangitis) together with biliary dilatation on imaging are part of the diagnostic workup of post-TACE biliary strictures. Cholangiography – either contrast-enhanced or MRCP – is eventually necessary for the localization and confirmation of the BS[10]. Endoscopic balloon dilation and multistenting treatment either with plastic or metallic stents represents the treatment of choice; however, in case of serrated stenosis, endoscopic treatment can be unsuccessful and may require radiological permanent biliary drainage or a surgical treatment.

BDN is a stage that precedes overt biloma. When treated promptly, most intrahepatic bilomas have an excellent outcome. Patients who develop bilomas following TACE have a mortality incidence of between 5% and 10%[17]. Therefore, early detection of BDN and biloma on imaging and extra careful management might be mandatory to improve patient prognosis after repeated TACE for liver tumors.

FOOTNOTES

Author contributions: Cocca S contributed to conceptualization and writing - original draft; Carloni L, Marocchi M, Bertani H, Bianchini M, Colecchia A contributed to contributed to writing - review & editing; Bertani H contributed to supervision; Marocchi M and Grande G contributed to review and figures editing; Conigliaro R contributed to supervision and conceptualization; All authors have read and approved the final manuscript.

Conflict-of-interest statement: All the authors declare no conflicts of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: Italy

ORCID number: Silvia Cocca 0000-0002-0642-8054; Lorenzo Carloni 0000-0002-9428-0757; Margherita Marocchi 0000-0002-3576-4620; Giuseppe Grande 0000-0003-3907-9740; Marcello Bianchini 0000-0003-4615-3777; Antonio Colecchia 0000-0002-8384-801X; Rita Conigliaro 0000-0002-2785-5952; Helga Bertani 0000-0003-0818-7167.

S-Editor: Liu JH

L-Editor: A

P-Editor: Xu ZH

REFERENCES

- 1 **European Association for the Study of the Liver.** EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J Hepatol* 2018; **69**: 182-236 [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019]
- 2 **Reig M,** Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. *J Hepatol* 2022; **76**: 681-693 [PMID: 34801630 DOI: 10.1016/j.jhep.2021.11.018]
- 3 **Mehta N,** Bhangu P, Yao FY, Mazzaferro V, Toso C, Akamatsu N, Durand F, Ijzermans J, Polak W, Zheng S, Roberts JP, Sapisochin G, Hibi T, Kwan NM, Ghobrial M, Soin A. Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. *Transplantation* 2020; **104**: 1136-1142 [PMID: 32217938 DOI: 10.1097/TP.0000000000003174]
- 4 **Micallef S,** Cortis K, Magri C. Hepatic Necrosis after Trans-Arterial Embolization of Metastatic Neuroendocrine Tumour. *Eur J Case Rep Intern Med* 2020; **7**: 001530 [PMID: 32399442 DOI: 10.12890/2020_001530]
- 5 **Sun W,** Xu F, Li X, Li CR. A Case Series of Liver Abscess Formation after Transcatheter Arterial Chemoembolization for Hepatic Tumors. *Chin Med J (Engl)* 2017; **130**: 1314-1319 [PMID: 28524831 DOI: 10.4103/0366-6999.206345]
- 6 **Lo YC,** Hsu PW, Chew FY, Chen HY. Special presentation of bronchobiliary fistula after transcatheter arterial chemoembolization: A case report. *Medicine (Baltimore)* 2022; **101**: e31596 [PMID: 36401479 DOI: 10.1097/MD.00000000000031596]
- 7 **Kim SI,** Jin YJ, Cho SG, Shin WY, Kim JM, Lee JW. Duodenal perforation and esophageal ischemia following transarterial

- chemoembolization for hepatocellular carcinoma: A case report. *Medicine (Baltimore)* 2016; **95**: e3987 [PMID: 27399074 DOI: 10.1097/MD.0000000000003987]
- 8 **Abdelrahman H**, Ajaj A, Atique S, El-Menyar A, Al-Thani H. Conservative management of major liver necrosis after angioembolization in a patient with blunt trauma. *Case Rep Surg* 2013; **2013**: 954050 [PMID: 24455392 DOI: 10.1155/2013/954050]
 - 9 **Loewe C**, Schindl M, Cejna M, Niederle B, Lammer J, Thurnher S. Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. *AJR Am J Roentgenol* 2003; **180**: 1379-1384 [PMID: 12704055 DOI: 10.2214/ajr.180.5.1801379]
 - 10 **Chan CH**, Telford JJ. Endoscopic management of benign biliary strictures. *Gastrointest Endosc Clin N Am* 2012; **22**: 511-537 [PMID: 22748246 DOI: 10.1016/j.giecc.2012.05.005]
 - 11 **Dumonceau JM**, Tringali A, Papanikolaou IS, Blero D, Mangiavillano B, Schmidt A, Vanbiervliet G, Costamagna G, Devière J, García-Cano J, Gyökeres T, Hassan C, Prat F, Siersema PD, van Hooft JE. Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated October 2017. *Endoscopy* 2018; **50**: 910-930 [PMID: 30086596 DOI: 10.1055/a-0659-9864]
 - 12 **Kaffes A**. Benign biliary strictures: how we are evolving to the perfect endoscopic strategy. *Endoscopy* 2019; **51**: 1115-1116 [PMID: 31775164 DOI: 10.1055/a-0981-6180]
 - 13 **Bill JG**, Mullady DK. Stenting for Benign and Malignant Biliary Strictures. *Gastrointest Endosc Clin N Am* 2019; **29**: 215-235 [PMID: 30846150 DOI: 10.1016/j.giecc.2018.12.001]
 - 14 **Coté GA**, Slivka A, Tarnasky P, Mullady DK, Elmunzer BJ, Elta G, Fogel E, Lehman G, McHenry L, Romagnuolo J, Menon S, Siddiqui UD, Watkins J, Lynch S, Denski C, Xu H, Sherman S. Effect of Covered Metallic Stents Compared With Plastic Stents on Benign Biliary Stricture Resolution: A Randomized Clinical Trial. *JAMA* 2016; **315**: 1250-1257 [PMID: 27002446 DOI: 10.1001/jama.2016.2619]
 - 15 **Wong MY**, Saxena P, Kaffes AJ. Benign Biliary Strictures: A Systematic Review on Endoscopic Treatment Options. *Diagnostics (Basel)* 2020; **10** [PMID: 32326542 DOI: 10.3390/diagnostics10040221]
 - 16 **Ponsioen CY**, Arnelo U, Bergquist A, Rauws EA, Paulsen V, Cantú P, Parzanese I, De Vries EM, van Munster KN, Said K, Chazouillères O, Desaint B, Kemgang A, Färkkilä M, Van der Merwe S, Van Steenberghe W, Marschall HU, Stotzer PO, Thorburn D, Pereira SP, Aabakken L. No Superiority of Stents vs Balloon Dilatation for Dominant Strictures in Patients With Primary Sclerosing Cholangitis. *Gastroenterology* 2018; **155**: 752-759.e5 [PMID: 29803836 DOI: 10.1053/j.gastro.2018.05.034]
 - 17 **Kobayashi S**, Kozaka K, Gabata T, Matsui O, Koda W, Okuda M, Okumura K, Sugiura T, Ogi T. Pathophysiology and Imaging Findings of Bile Duct Necrosis: A Rare but Serious Complication of Transarterial Therapy for Liver Tumors. *Cancers (Basel)* 2020; **12** [PMID: 32932894 DOI: 10.3390/cancers12092596]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

